Data completeness
4/8 — Partial
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ERMEZA is an oral solution NDA approved by Viatris in April 2022. The specific indication, mechanism of action, and pharmacologic class are not disclosed in available data. It represents a formulation-based product positioned in the oral solutions market.
$0.023MPart D
Peak8.3 years to LOEERMEZA is at peak lifecycle with minimal Part D penetration (83 claims), suggesting either niche indication or early adoption phase requiring focused commercial development.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ERMEZA offers limited current hiring signal (0 linked jobs), but as a peak-stage product at Viatris, opportunities exist in brand management, field sales, and medical affairs roles focused on market penetration and patient adoption. Long patent protection and minimal competitive pressure create a stable long-term career trajectory for commercial professionals.
Brand Manager
Worked on ERMEZA at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.